Brief: Equillium Inc - It Was Temporarily Pausing Enrollment In Its Equator Study

Equillium

31/10/2024 11:12

Oct 31 (Reuters) - Equillium Inc  EQ.O :
    * EQUILLIUM INC - IT WAS TEMPORARILY PAUSING ENROLLMENT IN
ITS
EQUATOR STUDY
    * EQUILLIUM INC - TEMPORARILY PAUSING ENROLLMENT IN EQUATOR
STUDY,
PHASE 3 CLINICAL STUDY OF ITOLIZUMAB (EQ001) IN ACUTE
GRAFT-VERSUS-HOST DISEASE
    * EQUILLIUM INC - REPOSITIONED ITOLIZUMAB (EQ001) AS ITS TOP
PRIORITY IN ITS PIPELINE
    * EQUILLIUM INC - TAKING OPERATIONAL STEPS TO EXTEND ITS
CASH
RUNWAY, WHICH MEASURES ARE EXPECTED TO PROVIDE OPERATING RUNWAY
INTO Q4 2025
    * EQUILLIUM INC - AS PART OF OPERATIONAL STEPS, COMPANY IS
PAUSING
FURTHER ACTIVITIES RELATED EQ101 AND EQ302
    * EQUILLIUM INC - EFFECTIVE OCT 30, OPTION AND ONO AGREEMENT
AUTOMATICALLY TERMINATED PURSUANT TO TERMS OF ONO AGREEMENT
    * EQUILLIUM INC - MAINTAINS ALL OF ITS COMMERCIAL RIGHTS TO
ITOLIZUMAB (EQ001)

Source text:  ID:n0001193125-24-248138 
Further company coverage:  EQ.O 

 ((Reuters.Briefs@thomsonreuters.com;))